DuPont’s specialty-materials transformation, healthcare and water exposure, and buybacks create an attractive re-rating opportunity despite material PFAS liabilities.
Overview
DuPont de Nemours has reshaped itself into a focused specialty-materials company following the November 1, 2025 separation of Qnity Electronics and the April 1, 2026, $1.8 billion Aramids divestiture. The remaining businesses serve healthcare, biopharma, water treatment, construction, aerospace, automotive and other applications where reliability, regulatory qualification and downtime avoidance support pricing power. **Q1 2026 validated the transformation:** sales increased 4% year over year to $1.681 billion, operating EBITDA rose 15% to $414 million, reported EBITDA margin expanded 230 basis points to 24.6%, and adjusted EPS reached $0.55 versus a $0.48 consensus estimate. Management raised FY 2026 sales guidance to $7.155-$7.215 billion and operating EBITDA guidance to $1.730-$1.760 billion. At the split-adjusted price of $138.00, DD trades at approximately 19.5x midpoint FY 2026 adjusted EPS of $7.09 and 3.02x EV/Sales versus a 4.42x market average. The principal catalyst is continued healthcare and water growth plus $1.2 billion of Aramids proceeds available for repurchases, while PFAS liabilities remain the key valuation overhang.